Treatment of Dyshidrotic Eczema
For dyshidrotic eczema, start with topical corticosteroids or topical tacrolimus as first-line therapy, escalate to phototherapy (PUVA or UVA1) for refractory cases, and reserve biologics like dupilumab or tralokinumab for severe, treatment-resistant disease.
First-Line Topical Therapy
Topical corticosteroids remain the mainstay of initial treatment for dyshidrotic eczema, with mometasone furoate 0.1% ointment demonstrating significant efficacy with >50% reduction in disease severity after 2 weeks of twice-daily application 1.
Topical tacrolimus 0.1% ointment is an effective alternative when corticosteroids are unsuitable or ineffective, showing comparable efficacy to mometasone furoate in reducing disease severity 2, 1.
Apply twice daily during active flares, with additional emollients used liberally 1.
Common pitfall: Most patients (14 of 16 in one study) experience symptom recurrence within 3 weeks after stopping active treatment, necessitating maintenance therapy or rotational strategies between tacrolimus and corticosteroids 1.
Second-Line Phototherapy
When topical therapies fail to control symptoms adequately:
PUVA (psoralen plus UVA) therapy is an established option for chronic hand eczema, with British guidelines recommending consideration of PUVA for treating patients with chronic hand eczema 2.
Localized high-dose UVA1 irradiation is equally effective as cream PUVA, reducing disease severity scores to half of pretreatment values, while being easier to perform and potentially safer by avoiding psoralen-related side effects 3.
Both modalities showed good response in 24 of 27 patients with no statistically significant difference in efficacy 3.
Third-Line Systemic Therapy for Severe Disease
For severe, refractory dyshidrotic eczema:
Dupilumab (standard dosing for atopic dermatitis) is the most established biologic option, with case reports demonstrating successful treatment of recalcitrant dyshidrotic eczema 4. The American Academy of Dermatology makes a strong recommendation for dupilumab use in atopic dermatitis spectrum disorders 5.
Tralokinumab represents a newer alternative, with successful treatment documented in severe dyshidrotic palmoplantar eczema, neutralizing IL-13 to address both itch and skin barrier defects 6. The AAD also makes a strong recommendation for tralokinumab in atopic dermatitis 5.
Alitretinoin should be offered to patients with severe chronic hand eczema per British guidelines, representing another systemic option 2.
Other immunomodulatory agents (azathioprine, cyclosporine, methotrexate, mycophenolate) receive conditional recommendations but are less specific for dyshidrotic eczema 5.
Avoid systemic corticosteroids as the AAD makes a conditional recommendation against their use due to unfavorable risk-benefit profile 5.
Treatment Algorithm
- Mild-to-moderate disease: Start with potent topical corticosteroids (mometasone furoate) twice daily for 4 weeks 1
- Corticosteroid concerns or tachyphylaxis: Switch to topical tacrolimus 0.1% twice daily 2, 1
- Inadequate response after 4-6 weeks: Add or switch to phototherapy (PUVA or UVA1) 2, 3
- Severe or refractory disease: Initiate dupilumab or tralokinumab at standard atopic dermatitis dosing 5, 6, 4
Key Clinical Considerations
Dyshidrotic eczema is considered part of the atopic dermatitis spectrum, which justifies using AD-approved biologics for severe cases 6, 4.
Expect chronic relapsing course requiring long-term management strategies rather than cure 1, 7.
Rotational therapy between tacrolimus and corticosteroids helps manage long-standing cases while minimizing adverse effects 1.
The disease significantly impacts quality of life and occupational function, with average annual direct costs exceeding $11 million across affected patients, justifying aggressive treatment escalation when needed 8.